ELUCIDATENCT05985655
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Trial sites expanded: 15 → 28 locations
- Minor Study sites: 13 to 15v8
- Minor Study sites: 12 to 13v7
- Notable Eligibility criteria expanded, about 2 words
- Enrollment target: 165 to 230
- Secondary endpoints: 6 to 7
Notable Lead sponsor: Exscientia AI Limited to Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.v5 Show 10 more changesShow less
- Eligibility criteria expanded, about 42 words
- Primary endpoints: 5 to 3
- Enrollment target: 170 to 165
- Study sites: 7 to 12
- Interventions: GTAEXS617 (Drug) to GTAEXS617 (Drug), SoC (Drug)
- Secondary endpoints: 3 to 6
- Study description shortened, about 62 words
- Study title revised
- Study arms: 1 to 4
- Collaborators shortened, about 3 words
Show 3 earlier versionsHide 3 earlier versions
- Minor Study sites: 6 to 7v4
- Minor Study sites: 2 to 6v3
- Minor Study sites: 1 to 2v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants will receive GTAEXS617 oral tablets in increasing doses.
Participants will receive GTAEXS617 oral tablets in increasing doses in combination with standard of care (SoC) treatment.
Participants will receive GTAEXS617 oral tablets at Recommended Phase 2 Dose (RP2D).
Participants will receive GTAEXS617 oral tablets at RP2D in combination with SoC treatment.
Drugs: GTAEXS617, SoC
Sites
28 sites in 3 countries
United States 19, United Kingdom 5, Belgium 4